Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR in Cushing's Disease
NCT01374906Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2011
- Primary completion
- Dec 2016
- Modality
- Peptides, Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of pasireotide LAR in Cushing's disease (CD), sponsored by Novartis. Started Nov 2011; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT01374906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01374906.